[OXFORD, OHIO, February 26, 2018] – Edward C. Jauch, MD, Professor and Chair of Emergency Medicine at the Medical University of South Carolina, presented positive clinical data demonstrating the ability of the ISCDxtm Test to identify cause of ischemic stroke at the 2018 International Stroke Conference held in Los Angeles, California. Dr. Jauch is lead Principal Investigator for the Biomarkers of Acute Stroke Etiology (BASE) clinical trial.
The analysis was statistically robust with Specificity = 95%, Sensitivity = 90.5%, and Area Under the Curve of 0.995, although it was noted this analysis had a very small sample size (32). Publication of a similar analysis from a much larger and statistically significant data set will occur later this year.
According to Jeff June, Ischemic Stroke Lab’s CEO and Founder, “The BASE clinical trial has recruited over 1,400 patients and was designed to analytically validate biomarkers for clinical use to identify stroke subtypes. The test uses a proprietary gene expression analysis of blood samples. Ischemia Care is the trial sponsor and is developing a series of blood tests for diagnosis and classification of stroke, TIA, and other neurological conditions. The first test, known as ISCDx, is a tool intended to help neurologists take the mystery out of cryptogenic stroke.”
In a recent interview a Vascular Neurologist noted that, “One of the bigger parts of stroke workup is figuring out why the heck somebody had a certain type of stroke. Sometimes it’s easy, but oftentimes, it kind of comes out of the blue. It’s a little mysterious.”
ISCDx is a quantitative tool to help streamline the stroke diagnostic workup and to identify patients with an undetected cardioembolic cause of stroke (such as atrial fibrillation). Proper diagnosis of the underlying cause of stroke enables guideline driven treatment to reduce risk of recurrence; currently 185,000 US patients have a recurrent stroke each year.